Jardiance Medicare Advantage Coverage: How to Get Empagliflozin for Less in 2026
At a glance
- Drug and form / empagliflozin (Jardiance), oral tablet, once daily [1]
- Brand / Jardiance, Boehringer Ingelheim, NDA 204629, first approved August 1, 2014 [4]
- Approved uses / heart failure, chronic kidney disease, cardiovascular death risk in type 2 diabetes with cardiovascular disease, blood sugar control in type 2 diabetes age 10 and older [1]
- Medicare negotiation / listed in a 2023 review among ten drugs set for CMS price negotiation in 2026 [2]
- Plan-level cost / set by each plan's formulary and benefit design
What determines whether a plan covers Jardiance
Each Medicare Advantage plan that includes drug coverage sets its own formulary, tier placement and prior authorization rules. Those terms are in the plan's formulary entry for empagliflozin or Jardiance. CMS describes its negotiation program as negotiating prices directly with participating drug companies for some of the costliest and most dispensed brand-name drugs used by people with Medicare [3]. A 2023 review listed empagliflozin among the ten drugs set to undergo CMS price negotiations in 2026 [2]; that listing does not show what any particular plan charges for Jardiance.
Is there a generic empagliflozin?
As of October 29, 2026, no generic empagliflozin label had been found in openFDA. Only Jardiance, repackagers of Jardiance and combination products with separate labels appeared: Synjardy (with metformin), Glyxambi (with linagliptin) and Trijardy XR. Jardiance is Boehringer Ingelheim's NDA 204629, first approved August 1, 2014 [4].
What the Jardiance label covers
The label lists four uses [1]:
- Heart failure: to reduce cardiovascular death and hospitalization for heart failure in adults. The label does not restrict this by ejection fraction.
- Chronic kidney disease at risk of progression: to reduce sustained eGFR decline, end-stage kidney disease, cardiovascular death and hospitalization.
- Type 2 diabetes with established cardiovascular disease: to reduce cardiovascular death.
- Type 2 diabetes: as an adjunct to diet and exercise to improve blood sugar control in adults and children aged 10 and older.
It has no weight indication. The label says it is not recommended for blood sugar control in type 1 diabetes, or in type 2 diabetes when eGFR is under 30 mL/min/1.73 m2 [1].
Dose and handling
The label gives 10 mg once daily in the morning, with or without food, for every indication. For additional blood sugar control in patients tolerating Jardiance, the dose may be increased to 25 mg once daily [1]. The label says to assess kidney function and volume status before starting, and to withhold Jardiance for at least 3 days, if possible, before surgery or procedures with prolonged fasting [1].
Where to find your plan's terms
The plan's formulary document and benefit summary state the Jardiance tier, whether prior authorization, step therapy or quantity limits apply, and the cost-sharing amount.
Frequently asked questions
Does Medicare Advantage cover Jardiance?
Is there a generic empagliflozin?
Is empagliflozin part of Medicare drug price negotiation?
What diagnoses does the Jardiance label cover?
References
- U.S. National Library of Medicine, DailyMed. Jardiance tablets (Boehringer Ingelheim) (empagliflozin) prescribing information. Jardiance tablets (Boehringer Ingelheim) (empagliflozin) label
- Jaksa A, Arena PJ, Gatto N. Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations. J Comp Eff Res. 2023;12(11):e230125. Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
- Home - Centers for Medicare & Medicaid Services | CMS. Home - Centers for Medicare & Medicaid Services | CMS
- Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs